Kathiawad Today

DelveInsight Estimates a Diverse Gastrointestinal Stromal Tumor Pipeline Comprising 25+ Companies Working in the Domain

 Breaking News
  • No posts were found

DelveInsight Estimates a Diverse Gastrointestinal Stromal Tumor Pipeline Comprising 25+ Companies Working in the Domain

March 06
21:40 2023
DelveInsight Estimates a Diverse Gastrointestinal Stromal Tumor Pipeline Comprising 25+ Companies Working in the Domain

DelveInsight’s, “Gastrointestinal Stromal Tumors Pipeline Insight 2023” report provides comprehensive insights about 25+ companies and 28+ pipeline drugs in Gastrointestinal Stromal Tumors pipeline landscape. It covers the Gastrointestinal Stromal Tumor pipeline drug profiles, including Gastrointestinal Stromal Tumor clinical trials and nonclinical stage products. It also covers the Gastrointestinal Stromal Tumor pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Gastrointestinal Stromal Tumor Emerging drugs, the Gastrointestinal Stromal Tumor pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Gastrointestinal Stromal Tumor pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Gastrointestinal Stromal Tumor Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Gastrointestinal Stromal Tumor clinical trials studies, Gastrointestinal Stromal Tumor NDA approvals (if any), and product development activities comprising the technology, Gastrointestinal Stromal Tumor collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Gastrointestinal Stromal Tumor Pipeline Report

 

  • DelveInsight’s Gastrointestinal Stromal Tumor Pipeline analysis depicts a robust space with 25+ active players working to develop 28+ pipeline treatment therapies.

 

  • The leading Gastrointestinal Stromal Tumor Companies includes Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

 

  • Promising Gastrointestinal Stromal Tumor Pipeline Therapies includes Famitinib, DS 6157, PLX9486, Anlotinib, Masitinib, Intuvax, Dovitinib, Ipilimumab, L-carnitine, Pazopanib, Nilotinib, HQP1351, PDR001, Ponatinib, MEK162, Crenolanib besylate, XmAb18087, TNO155, DNX-2440, Palbociclib, Cabozantinib, Pamufetinib, THE-630, IDRX-42, and others.

 

  • The Gastrointestinal Stromal Tumor companies and academics are working to assess challenges and seek opportunities that could influence Gastrointestinal Stromal Tumors (GIST) R&D. The Gastrointestinal Stromal Tumor pipeline therapies under development are focused on novel approaches to treat/improve Gastrointestinal Stromal Tumors (GIST).

 

Request a sample and discover the recent breakthroughs happening in the Gastrointestinal Stromal Tumor Pipeline landscape @ Gastrointestinal Stromal Tumor Pipeline Outlook Report

 

Gastrointestinal Stromal Tumor Overview

Gastrointestinal Stromal Tumors (GIST) (GISTs) are among a group of cancers known as sarcomas. GISTs belong to the family of sarcomas, which are malignant tumors that arise from various tissues, including fat, muscle, nerves, cartilage, bone, blood vessels, and lymphatic vessels. This distinguishes sarcomas from carcinomas, which arise from the lining of organs/tissues (e.g., lung, colon, breast, prostate, and pancreas), lymphomas, which arise from immune cells in lymph nodes, and leukemias, which arise from immune cells in the bone marrow. GIST can present with a wide spectrum of subjective symptoms, such as nausea, early satiety, bloating, and weight loss. Patients can also experience objective signs of a tumor, such as anemia (low red blood cell count) or a lump in the abdomen. These signs and symptoms depend on the tumor location (e.g., stomach versus rectum), size, and pattern of growth.

 

Recent Developmental Activities in the Gastrointestinal Stromal Tumors Treatment Landscape

 

  • In June 2022, Immunicum AB was granted an Orphan Drug Designation (ODD) from the US Food and Drug Administration (FDA) for ilixadencel in the treatment of Gastrointestinal Stromal Tumors (GIST). 

 

  • PLX9486 is a selective tyrosine kinase inhibitor designed to inhibit KIT exon 17 mutations, including D816V potently. Most patients with imatinib-resistant GIST have both primary and secondary KIT mutations, often including secondary mutations on exon 17 and exon 13, making it difficult to achieve broad therapeutic KIT inhibition. Cogent Biosciences, Inc. will present lead-in data from PEAK, a registrational randomized, open-label, global, Phase III clinical trial in patients with gastrointestinal stromal tumors (GIST), in the first half of 2023. 

 

  • In June 2022, Ascentage Pharma announced the latest results from a Phase Ib/II study of the third-generation tyrosine kinase inhibitor (TKI) olverembatinib (HQP1351) in patients with metastatic gastrointestinal stromal tumor (GIST) who were resistant to or failed prior TKI treatment. The company reported the promising antitumor activity of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). In July 2021, Ascentage Pharma and Innovent Biologics (1801.HK) reached the agreement regarding the joint development and commercialization of olverembatinib in the oncology field in China.

 

  • In January 2022, Theseus Pharmaceuticals, announced that the first patient has been treated in the Phase I portion of Theseus’ ongoing Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST). The initial data is expected in 1H 2023. In February 2022, US Food and Drug Administration granted orphan drug designation (ODD) to the company’s lead candidate THE-630, for the treatment of patients with advanced gastrointestinal stromal tumors (GIST).

 

  • IDRX-42 and IDRX-73 are both small molecule tyrosine kinase inhibitors (TKIs) being developed by Idrx Inc. These are designed to inhibit the key genetic drivers and drug-resistant mutations of gastrointestinal stromal tumor (GIST). The goal is for IDRX-42 to serve as a great base of therapy for GIST patients, and that when IDRX-73 is added, the combination may provide a transformative benefit.

 

For further information, refer to the detailed Gastrointestinal Stromal Tumor Drugs Launch, Gastrointestinal Stromal Tumor Developmental Activities, and Gastrointestinal Stromal Tumor News, click here for Gastrointestinal Stromal Tumor Ongoing Clinical Trial Analysis

 

Gastrointestinal Stromal Tumor Emerging Drugs Profile

 

  • Famitinib: Jiangsu Hengrui Medicine

Famitinib, an orally active, small molecule, is a tyrosine kinase inhibitor against multiple targets, including vascular endothelial growth factor receptor 2/3, platelet-derived growth factor receptor, and stem cell factor receptor (c-kit). Jiangsu Hengrui Medicine Co is developing famitinib against a wide variety of advanced-stage solid cancers. The drug is currently in phase 3 of clinical development for the treatment of Gastrointestinal Stromal Tumors (GIST).

 

  • Nilotinib: Novartis

Tasigna (nilotinib hydrochloride monohydrate) is an orally available signal transduction inhibitor of the Bcr-Abl kinase, c-kit and Platelet Derived Growth Factor (PDGF), all of which play a role in cell proliferation, cell migration, and angiogenesis. Tasigna is specifically indicated for the treatment of chronic phase and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (CML) in adult patients resistant or intolerant to prior therapy that included imatinib. The drug is currently being investigated in Phase II clinical trial to evaluate its potential for the treatment of gastrointestinal stromal tumors.

 

  • THE-630: Theseus Pharmaceuticals

THE-630 is a pan-variant inhibitor of the receptor tyrosine kinase KIT. It is designed for patients with advanced GIST whose cancer has developed resistance to earlier lines of therapy by accruing mutations that render those therapies ineffective. In GIST, these mutations occur most often in the KIT protein, where a patient can have multiple KIT mutations simultaneously, leading to complex disease heterogeneity. In preclinical studies, THE-630 demonstrated potent in vitro and in vivo activity against all major classes of KIT activating and resistance mutations in GIST. Moreover, THE-630 achieved predicted pan-variant KIT inhibitory blood concentrations at tolerable doses and was associated with significant anti-tumor activity. Theseus Pharmaceuticals is currently conducting Phase I/II study to evaluate lead candidate, THE-630, in patients with advanced gastrointestinal stromal tumors (GIST).

 

  • DS 6157: Daiichi Sankyo Company

DS-6157 is a potential first-in-class GPR20 targeting ADC and the fifth DXd ADC in the oncology pipeline of Daiichi Sankyo to enter clinical development. ADCs are targeted cancer medicines that deliver cytotoxic chemotherapy (“payload”) to cancer cells via a linker attached to a monoclonal antibody that binds to a specific target expressed on cancer cells. Designed utilizing Daiichi Sankyo’s proprietary DXd ADC technology, DS-6157 is comprised of a humanized anti-GPR20 monoclonal antibody, which is attached to a novel topoisomerase I inhibitor payload by a tetrapeptide-based linker. The drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors.

 

Gastrointestinal Stromal Tumor Pipeline Therapeutics Assessment

There are approx. 25+ key companies which are developing the therapies for Gastrointestinal Stromal Tumors. The companies which have their Gastrointestinal Stromal Tumors drug candidates in the most advanced stage, i.e. phase III include, Jiangsu Hengrui Medicine.

 

Find out more about the Gastrointestinal Stromal Tumor Pipeline Segmentation, Therapeutics Assessment, and Gastrointestinal Stromal Tumor Emerging Drugs @ Gastrointestinal Stromal Tumor Treatment Landscape

 

Scope of the Gastrointestinal Stromal Tumor Pipeline

 

  • Coverage- Global

 

  • Gastrointestinal Stromal Tumor Companies- Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor, Inc., DNAtrix, Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx, Inc., Allarity Therapeutics, and others.

 

  • Gastrointestinal Stromal Tumor Pipeline Therapies- Famitinib, DS 6157, PLX9486, Anlotinib, Masitinib, Intuvax, Dovitinib, Ipilimumab, L-carnitine, Pazopanib, Nilotinib, HQP1351, PDR001, Ponatinib, MEK162, Crenolanib besylate, XmAb18087, TNO155, DNX-2440, Palbociclib, Cabozantinib, Pamufetinib, THE-630, IDRX-42, and others.

 

  • Gastrointestinal Stromal Tumor Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration

  

Dive deep into rich insights for drugs for Gastrointestinal Stromal Tumor Pipeline Companies and Therapies, click here @ Gastrointestinal Stromal Tumor Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Gastrointestinal Stromal Tumors: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Gastrointestinal Stromal Tumors – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Famitinib: Jiangsu Hengrui Medicine
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Nilotinib: Novartis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. DS 6157: Daiichi Sankyo Company
  15. Drug profiles in the detailed report…..
  16. Inactive Products
  17. Gastrointestinal Stromal Tumors Key Companies
  18. Gastrointestinal Stromal Tumors Key Products
  19. Gastrointestinal Stromal Tumors- Unmet Needs
  20. Gastrointestinal Stromal Tumors- Market Drivers and Barriers
  21. Gastrointestinal Stromal Tumors- Future Perspectives and Conclusion
  22. Gastrointestinal Stromal Tumors Analyst Views
  23. Gastrointestinal Stromal Tumors Key Companies
  24. Appendix

 

Got Queries? Find out the related information on Gastrointestinal Stromal Tumor Mergers and acquisitions, Gastrointestinal Stromal Tumor Licensing Activities @ Gastrointestinal Stromal Tumor Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/